欢迎访问西北工业大学生命学院网站,新版本上线试运行中!ENGLISH  学校主页  联系我们    
 首 页  学院概况  机构设置  师资队伍  学科建设  教学工作  科学研究  重点实验室  党群工作  学生工作  人才培养  招生就业 
新闻中心
 院系新闻 
 学术交流 
 通知公告 
学术交流
当前位置: 首 页>>新闻中心>>学术交流>>正文
【学术报告】芬兰奥博学术大学Hongbo Zhang(张宏博)学术报告
  审核人:

报告题目:Development of Nanoparticles for Clinical Research 

报 告 人:Hongbo Zhang副教授 

报告时间:2019年6月19日(星期三)下午14:30

报告地点:西馆XA208

邀 请 人: 卢婷利教授,尹大川教授

承办学院:生命学院

联系电话:17391910270

人物简介:

说明: A person wearing a suit and tie smiling at the cameraDescription automatically generated

张宏博,芬兰奥博学术大学副教授,上海交通大学特聘客座教授

张宏博博士2012年12月毕业于赫尔辛基大学制药系。拥有生物制药,纳米科技,微流体技术,癌症精准医疗,细胞和分子生物学等方面的交叉科研背景,掌握国际领先水准的相关知识技能。发表SCI论文超过80篇,包括影响因子10分以上的顶级文章23篇。在芬兰和中国以第一负责人主持15个大型项目,总资金超过2000万人民币。作为合作人参与多项大型国际合作项目,总资金超过4亿人民币。在微流体和纳米医学领域,师从美国三院院士,哈佛大学David A. Weitz教授。2016年9月,入职芬兰埃博学术(Åbo Akademi University)大学,担任助理教授,并建立了纳米精致医疗课题组。与哈佛大学合作,在埃博学术大学首次搭建了微流体纳米及微米粒子合成平台及微流体单细胞分析平台。并被芬兰图尔库生物技术中心聘为课题组组长,与合作者共同组建了Single Cell Omics平台,该平台处于世界领先地位,预期将成为专业领域芬兰第一,欧洲前五的单细胞分析平台。2018年11月,基于优异的表现,让埃博学术大学打破了TenureTrack的3年评审规则,提前评审为副教授。张宏博博士注重于产学研结合,目前有多项专利在进行申请,并和淮海融泰控股集团联合,投资5000万人民币,组建了中芬生物科技高新产业孵化基地,兼职执行董事。另外,张宏博博士也积极参加社会活动,担任芬兰华人科技协会会长,北欧致公协会副会长,芬兰市长协会会员,曾多次接待国家省部级领导到芬兰考察,并为中芬两国合作做出重大贡献。2017年及2018年,作为优秀华人,两次在北京被政协副主席,原科技部部长万钢接见。

研究内容简介:

Introduction/Purpose

Nanotechnology has provided revolutionary impacts for the traditional medication. The nanometer size is highly relevant to many biological conditions, for example 50-200 nm particles tend to accumulate in tumor tissue due to the enhanced permeability and retention (EPR) effect. Moreover, the nanoparticles can be endowed with character of smart, responsive, targeted, multi-functional and etc. However, there are also distinct challenges for nano-medication, including the toxicity, cost, unwanted immune response, industry scale fabrications etc. More research focuses should be taken in the clinical translation of nanomaterials.

Methods

Our research focuses on the development of functional nanomaterials for solving real clinical problems. We have multidisciplinary team from chemistry, material science, engineering, medicine and biology. We always initial the project with clinical doctors and their clinical questions, and the clinical doctors and/or medical students are involved in the projects from start to the end. We synthesize all kinds of nanomaterials, and we are especially interested in mesoporous silica

nanoparticles, the synthetic and nature polymers, DNA nanoparticles and etc. We also apply microfluidic technology for nanoparticles and microparticles fabrication.

Results

Here we present the examples on how we utilized functional materials and microfluidics for different types of applications. Including, targeted cancer drug delivery, cancer immune therapy, image-guided cancer surgery, biosensor for diagnostics, scaffold and hydrogel for wound healing and spinal cord regeneration, and biomimetic scaffold for bone regeneration etc. Moreover, we present how Microfluidics improve the monodisperse, reproducibility and efficiency of the nano-fabrication.

Conclusions

Different types of nanomaterials have shown great potential in diagnostics, imaging, therapy and

especially in consideration of precision nano-medication. Moreover, microfluidics enable the industrial scale fabrication of nanoparticles. We hope very much that you will find hints from those examples on the clinical translational potential.

Selected references

[1] Y. Yan, H. Chen, H. Zhang, C. Guo, K. Yang, K. Chen, R. Cheng, N. Qian, N. Sandler, Y. S. Zhang, Biomaterials 2019, 190, 97.

[2] Z. Liu, Y. Li, W. Li, W. Lian, M. Kemell, S. Hietala, P. Figueiredo, L. Li, E. Mäkilä, M. Ma, Materials Horizons 2019.

[3] Y. Zhu, H. Zhang, Y. Zhang, H. Wu, L. Wei, G. Zhou, Y. Zhang, L. Deng, Y. Cheng, M. Li, Adv. Mater. 2018, 1805452.

[4] R. Zhong, Q. Tang, S. Wang, H. Zhang, F. Zhang, M. Xiao, T. Man, X. Qu, L. Li, W. Zhang, Adv. Mater. 2018, 30, 1706887.

[5] Y. Zhang, J. Tu, D. Wang, H. Zhu, S. K. Maity, X. Qu, B. Bogaert, H. Pei, H. Zhang, Adv. Mater. 2018, http://onlinelibrary.wiley.com/doi/10.10.

[6] H. Zhang, Y. Zhu, L. Qu, H. Wu, H. Kong, Z. Yang, D. Chen, E. Mäkilä, J. Salonen, H. A. Santos, Nano Lett. 2018, 18, 1448.

[7] Y. Yan, T. Sun, H. Zhang, X. Ji, Y. Sun, X. Zhao, L. Deng, J. Qi, W. Cui, H. A. Santos, Adv. Funct. Mater. 2018, 1807559.

[8] S. Qi, P. Zhang, M. Ma, M. Yao, J. Wu, E. Mäkilä, J. Salonen, H. Ruskoaho, Y. Xu, H. A. Santos, Small 2018, 1804332.

[9] X. Mao, R. Cheng, H. Zhang, J. Bae, L. Cheng, L. Zhang, L. Deng, W. Cui, Y. Zhang, H. A. Santos, Advanced Science 2018, 1801555.

[10] Z. Liu, Y. Li, W. Li, C. Xiao, D. Liu, C. Dong, M. Zhang, E. Mäkilä, M. Kemell, J. Salonen, Adv. Mater. 2018.

[11] D. Liu, H. Zhang, F. Fontana, J. T. Hirvonen, H. A. Santos, Adv. Drug Deliv. Rev. 2018, 128, 54.

[12] J. Ji, F. Ma, H. Zhang, F. Liu, J. He, W. Li, T. Xie, D. Zhong, T. Zhang, M. Tian, Adv. Funct. Mater. 2018, 1801738.

[13] H. Zhang, D. Liu, M. A. Shahbazi, E. Mäkilä, B. Herranz‐Blanco, J. Salonen, J. Hirvonen, H. A. Santos, Adv. Mater. 2014, 26, 4497.

关闭窗口

友情链接:

版权所有©2004-2011 西北工业大学生命学院

院系地址:陕西省 西安市 西北工业大学生命学院 邮编:710072